CAR therapy for Alzheimer’s: reprogramming brain cells to fight the disease from within
The same technique that has transformed cancer treatment — reprogramming immune cells to hunt down disease — is now being aimed at Alzheimer’s.
CAR therapy works by engineering cells to carry a synthetic receptor that recognises and attacks a specific target. In cancer, this has produced dramatic results. Now, a study published in Nature Aging applies the same logic to Alzheimer’s disease — a condition that still lacks any treatment capable of halting its progression. The twist: rather than using T-cells from the immune system, the researchers focused on astrocytes, support cells native to the central nervous system that in Alzheimer’s become dysfunctional and fuel inflammation.
In Alzheimer’s, two proteins — amyloid-beta and tau — accumulate in the brain and drive the death of nerve cells. Drugs targeting amyloid, such as lecanemab, have shown modest effects but come with significant risks including brain swelling. The question the new study posed was different: could you turn cells already present in the brain into a dedicated cleanup crew?
Reprogramming the brain’s own support system
Using gene therapy, the researchers equipped astrocytes with a chimeric antigen receptor — the CAR — designed to recognise molecular signatures associated with Alzheimer’s pathology. Once activated, these modified astrocytes degrade harmful protein aggregates and suppress inflammatory signalling. In mouse models of Alzheimer’s, the approach reduced amyloid plaques and improved performance on memory and orientation tasks.
The choice of astrocytes as the therapeutic platform is strategically significant. Unlike CAR-T therapies for brain tumours, which require injecting engineered cells from outside and breaching the blood-brain barrier, this approach reprograms cells that are already where they need to be. That sidesteps one of the biggest logistical and safety challenges in treating brain diseases.
A long road from mice to patients
The history of Alzheimer’s research is littered with treatments that worked in mice and failed in humans. Rodent models don’t replicate the full complexity of the human disease — the genetic background differs, the brain architecture is simpler, and the timeline of pathology doesn’t match. Genetically altering astrocytes in a living brain also raises questions about long-term safety that mouse experiments cannot answer: how permanent is the reprogramming, how specific is the targeting, and what are the consequences of sustained astrocyte activation?
No clinical trials in humans have been announced. What the study does represent is a shift in therapeutic thinking — away from external drugs targeting amyloid after the fact, toward recruiting the brain’s own cellular architecture as an active participant in defence. Whether that architecture can be safely and durably reprogrammed in humans is the question this field will have to answer next.